Also trades as: 0HF9.L (LSE) · $vol 0M
FOLD NASDAQ
Amicus Therapeutics, Inc.
1W: +0.2%
1M: +0.4%
3M: +1.4%
YTD: +1.5%
1Y: +101.2%
3Y: +26.0%
5Y: +48.0%
$14.49
Last traded 2026-04-27 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships7
As Filer
counterparties named
2
As Counterparty
mentioned by others
4
Rel. Types
2022-12-28
Earliest Filing
2026-02-12
Latest Filing
supplier: 3
partner: 2
acquirer: 1
target: 1
Counterparties (Filed by FOLD)
7 relationshipsCompanies named in FOLD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc. | BMRN | acquirer | Acquired Amicus Therapeutics, Inc. in a merger transaction. | 2025-12-19 | View |
| Lynx Merger Sub 1, Inc. | — | target | Wholly owned subsidiary of BioMarin used as the merger vehicle to acquire Amicus Therapeutics, Inc. | 2025-12-19 | View |
| Dimerix Bioscience Pty Ltd | — | partner | Exclusive license agreement for DMX-200 development and commercialization in the US | 2025-05-01 | View |
| WuXi Biologics (Hong Kong) Limited | — | supplier | Agreement to manufacture and supply API and finished drug product | 2023-04-24 | View |
| WuXi Biologics Ireland Limited | — | supplier | Agreement to manufacture and supply API and finished drug product | 2023-04-24 | View |
| WuXi Biologics Germany GmbH | — | supplier | Agreement to manufacture and supply API and finished drug product | 2023-04-24 | View |
| University of Pennsylvania | — | partner | Partnered with Amicus Therapeutics for wind-down activities and licensing of gene therapy technology. | 2022-12-28 | View |
Mentioned As Counterparty
2 mentionsOther companies that named FOLD in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| BMRN BIOMARIN PHARMACEUTICAL INC | acquirer | Target of the pending acquisition funded by the Notes and Term Loan facilities. | 2026-02-12 | View |
| BMRN BIOMARIN PHARMACEUTICAL INC | acquirer | Target company in the proposed merger agreement with BioMarin Pharmaceutical Inc. | 2025-12-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-04-27 | Termination of Agreement; Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Dire | Acquisition | View |
| 2026-04-23 | Other Events | View | |
| 2026-03-03 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2026-02-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-26 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-12-19 | Entry into Material Definitive Agreement; Amendments to Articles of Incorporation or Bylaws; Regulat | Agreement | View |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-01 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-21 | Financial Statements and Exhibits | View | |
| 2025-02-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-17 | Other Events | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-07 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2024-05-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-02-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR